Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
Ecem BuyukyanboluLeyla GencElizabeth A CyrMehmet KarakusFusun ComertBaris OtluElif AktasDavid P NicolauPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)
While ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against CR-PA devoid of carbapenemases, cefiderocol provided potent in vitro activity irrespective of carbapenemase production. When considering the potential clinical utility of newer agents against CR-PA, regional variations in carbapenemase prevalence must be considered.